Microscopic polyangiitis epidemiology and demographics

Revision as of 20:59, 20 April 2018 by Gunnam (talk | contribs) (→‎Race)
Jump to navigation Jump to search

Microscopic polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microscopic polyangiitis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis epidemiology and demographics

CDC on Microscopic polyangiitis epidemiology and demographics

Microscopic polyangiitis epidemiology and demographics in the news

Blogs on Microscopic polyangiitis epidemiology and demographics

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]

Overview

The prevalence of Microscopic polyangiitis ranges from 1 to 3 per 100,000 a year, with higher prevalence rates occurring in Southern European countries and Asia. The incidence of the disease is 5.9 per million a year in the United Kingdom.The incidence of GPA was similar to that of MPA.MPO‐ANCAs when positive in a patient were a marker of poor prognosis in the population of patients with AAV.

Epidemiology

Incidence

  • The incidence of Microscopic polyangiitis is approximately 3.3 per 100,000 individuals worldwide.[1]
  • Microscopic polyangiitis in Europe is seen with higher incidences in Southern countries than in Northern countries. [2]
  • The incidence of Microscopic polyangiitis is estimated to be 5.9 per million persons per year in the United Kingdom.[3]
  • During the last two decades the incidences of Microscopic polyangiitis has increased, which is due to the availability of testing for ANCA.

Prevalence

  • The prevalence of Microscopic polyangiitis is approximately 42.1 per 100,000 individuals worldwide.[4]

Age

  • The incidence of Microscopic polyangiitis increases with age; the median age at diagnosis is 60 years.[5]

Gender

  • Males are more commonly affected with Microscopic polyangiitis than females (1.8:1).[6]

Race

  • Microscopic polyangiitis tends to affect individuals of Asian and Southern European descent.[7]

Mortality rate

  • MPO‐ANCAs were a marker of poor survival and increased mortality rate in this population of patients with AAV.[8]

References

  1. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL (December 2017). "The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study". Arthritis Rheumatol. 69 (12): 2338–2350. doi:10.1002/art.40313. PMID 28881446.
  2. Chung SA, Seo P (2010). "Microscopic polyangiitis". Rheum Dis Clin North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
  3. Watts RA, Mooney J, Skinner J, Scott DG, Macgregor AJ (2012). "The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis". Rheumatology (Oxford). 51 (5): 926–31. doi:10.1093/rheumatology/ker454. PMC 3465699. PMID 22258386.
  4. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL (December 2017). "The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study". Arthritis Rheumatol. 69 (12): 2338–2350. doi:10.1002/art.40313. PMID 28881446.
  5. Mohammad, A. J.; Jacobsson, L. T. H.; Mahr, A. D.; Sturfelt, G.; Segelmark, M. (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden". Rheumatology. 46 (8): 1329–1337. doi:10.1093/rheumatology/kem107. ISSN 1462-0324.
  6. Mohammad, A. J.; Jacobsson, L. T. H.; Mahr, A. D.; Sturfelt, G.; Segelmark, M. (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden". Rheumatology. 46 (8): 1329–1337. doi:10.1093/rheumatology/kem107. ISSN 1462-0324.
  7. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, Hashimoto H, Nunoi H (October 2011). "Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K". Rheumatology (Oxford). 50 (10): 1916–20. doi:10.1093/rheumatology/ker205. PMID 21798892.
  8. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL (December 2017). "The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study". Arthritis Rheumatol. 69 (12): 2338–2350. doi:10.1002/art.40313. PMID 28881446.

Template:WH Template:WS